A Comparative Study of the Effects of Adrenoceptor Antagonists on Platelet Aggregation and Thromboxane Generation

 

PDF Download Buy Article Permissions and Reprints

Summary

Platelet aggregation and thromboxane A₂ have been implicated in the pathogenesis of several forms of vascular disease. The aim of this study was to determine the effect of a wide range of adrenoceptor antagonists on platelet aggregation, and thromboxane A₂ production, from normal human platelet rich plasma in vitro. Labetalol, pindolol and propranolol inhibited platelet aggregation to collagen in a dose dependent manner. Increasing the concentration of collagen “shifted” the dose response curve to the right. These 3 drugs also significantly inhibited thromboxane A₂ generation in response to collagen but not to arachidonic acid. This effect was independent of any inhibitory effect of these drugs on platelet aggregation, and occurred at a drug concentration close to that obtained in vivo. Atenolol, metoprolol, prazosin and timolol were similarly assessed but had no effect on either platelet aggregation or thromboxane A₂ generation. This ability of labetalol, pindolol, and propranolol to inhibit platelet aggregation and thromboxane generation, may be of clinical benefit in view of the increasing evidence implicating thromboxane A₂ in the pathogenesis of vascular disease.

• References

• 1 Steele PP, Weily HS, Davies H, Genton E. Platelet function in coronary artery disease. Circulation 1973; 48: 1194-1200
  CrossrefPubMedGoogle Scholar
• 2 Murphy EA, Mustard JF. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation 1962; 25: 114-125
  CrossrefPubMedGoogle Scholar
• 3 Harker LA, Slichter S. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
  CrossrefPubMedGoogle Scholar
• 4 Metha J, Metha P, Pepine CJ. Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease III. Role of tachycardia, stress and propranolol. Circulation 1978; 58: 881-886
  CrossrefPubMedGoogle Scholar
• 5 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2294-2298
  CrossrefPubMedGoogle Scholar
• 6 Schror K, Smith III EF, Bickerton M, Smith JB, Nicolaou KC, Magolda R, Lefer AM. Preservation of ischaemic myocardium by pinane thromboxane A₂ . Am J Physiol 1980; 238: H87-H92
  PubMedGoogle Scholar
• 7 Coker J, Parratt JR. Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol 1983; (Suppl. 15) 87-96
  PubMedGoogle Scholar
• 8 Lewy RI, Wrener L, Smith JB, Walinsky P, Silver MJ, Saia J. Comparison of plasma concentrations of thromboxane B₂ in prinzmetals variant angina and classical angina pectoris. Clin Cardiol 1979; 2: 404-406
  CrossrefPubMedGoogle Scholar
• 9 Robertson RM, Robertson D, Roberts LJ, Maas RL, Fitzgerald GA, Friesinger GC, Oates JA. Thromboxane A₂ in vasotonic angina pectoris. N Eng J Med 1981; 304: 998-1003
  CrossrefPubMedGoogle Scholar
• 10 Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischaemic heart disease. N Engl J Med 1981; 304: 685-691
  CrossrefPubMedGoogle Scholar
• 11 Frishman WH, Weksler B, Christodoulou JF, Smithen C, Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974; 50: 887-898
  CrossrefPubMedGoogle Scholar
• 12 Campbell WB, Johnson AR, Callahan KS, Graham RM. Antiplatelet activity of beta-adrenergic antagonists: Inhibition of thromboxane synthesis and platelet aggregation in patients receiving longterm propranolol treatment. Lancet 1981; 2: 1382-1384
  PubMedGoogle Scholar
• 13 Weksler BB, Gillick M, Pink J. Effects of propranolol on platelet function. Blood 1977; 49: 185-196
  PubMedGoogle Scholar
• 14 Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, Scheidt S. Abrupt propranolol withdrawal in angina pectoris; effects on platelet aggregation and exercise tolerance. Am Heart J 1978; 95: 169-179
  CrossrefPubMedGoogle Scholar
• 15 Rubegni M, Provvedi D, Bellini PG. Beta blocking agents and platelet aggregation. JAMA 1974; 228: 462
  PubMedGoogle Scholar
• 16 Small M, Douglas JT, Aherne GW, Orr M, Lowe GDO, Forbes CD, Prentice CRM. Effects of the non-selective beta-adrenoceptor blocking agent, carteolol, on platelet function, blood coagulation and viscosity. Thromb Res 1982; 25: 351-360
  CrossrefPubMedGoogle Scholar
• 17 Campbell WB, Callahan KS, Johnson AR, Hirsh PD. Mechanism of the antiplatelet activity of beta-adrenergic antagonists. Prog Clin Pharmacol 1981; 3: 117-126
  PubMedGoogle Scholar
• 18 Dachany-Prigent J, Dufourcq J, Lussan C, Boisseau M. Propranolol, chlorpromazine and platelet membrane; a fluorescence study of the drug membrane interaction. Thromb Res 1979; 14: 15-22
  CrossrefPubMedGoogle Scholar
• 19 Heinroth I, Block HU, Ponicke K, Forster W. Influence of propranolol, pindolol, practolol and talinolol on arachidonic acid (AA) and U-46619-induced aggregation and on AA-induced thromboxane A₂ formation in platelets. Prostaglands Leuk Med 1983; 12: 189-206
  PubMedGoogle Scholar
• 20 Mehta J, Mehta P. Effect of propranolol therapy on platelet release and prostaglandin generation in patients with coronary artery disease. Circulation 1982; 66: 1294-1299
  CrossrefPubMedGoogle Scholar
• 21 Mehta J, Mehta P, Ostrowski N. Influence of propranolol and 4-hydroxypropranolol on platelet aggregation and thromboxane A₂ generation. Clin Pharmacol Ther 1983; 34: 559-564
  CrossrefPubMedGoogle Scholar
• 22 Born GVR. Aggregation of blood platelets by ADP and its reversal. Nature 1962; 194: 927-929
  PubMedGoogle Scholar
• 23 Granstrom L, Kindahl H. Radioimmunoassay of prostaglandins and thromboxanes. In Advances in prostaglandin and thromboxane research. Frolich JC. (ed) 1978. 5 119-210
  Google Scholar
• 24 Bakhle YS. Synthesis and catabolism of cyclo-oxygenase products. Br Med Bull 1983; 39: 214-218
  CrossrefPubMedGoogle Scholar
• 25 Blackwell GJ, Flower RJ. Inhibition of phospholipase. Br Med Bull 1983; 39: 260-264
  CrossrefPubMedGoogle Scholar
• 26 Nachmias VT, Kavaler J, Jacubowitz S. Reversible association of Myosin with the platelet cytoskeleton. Nature 1985; 313: 70-72
  CrossrefPubMedGoogle Scholar
• 27 Green D, Rossi EC, Haring O. The B-blocker heart attack trial: studies of platelets and factor VIII. Thromb Res 1982; 28: 261-267
  CrossrefPubMedGoogle Scholar
• 28 Norwegian Multicentre Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807
  CrossrefPubMedGoogle Scholar
• 29 Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Halek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Wilhelmsen L, Wilkelmsson C. Effect on mortalitiy of metoprolol in acute myocardial infarction. Lancet 1981; 2: 823-826
  PubMedGoogle Scholar
• 30 Feely J, de Vane PJ, MacLean D. Beta-blockers and sympathomimetics. Br Med J 1983; 286: 1043-1046
  CrossrefPubMedGoogle Scholar
• 31 Woods PB, Robinson ML. An investigation of the comparative liposolubilities of B-adrenoceptor blocking agents. J Pharm Pharmacol 1981; 33: 172-173
  CrossrefPubMedGoogle Scholar
• 32 Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part I pharmacodynamic and pharmacokinetic properties. Am Heart J 1979; 97: 663-670
  CrossrefPubMedGoogle Scholar
• 33 Wood AJ, Bolli P, Simpson FO. Prazosin in normal subjects: plasma levels, blood pressure and heart rate. Br J Clin Pharmacol 1976; 3: 199-201
  CrossrefPubMedGoogle Scholar